新型抗癫痫药物进展报告：第十一届依莱克托会议（EILAT XI）总结。

Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI).

机构信息

Institute for Drug Research, School of Pharmacy and David R. Bloom Center for Pharmacy, Faculty of Medicine, Ein Karem, The Hebrew University of Jerusalem, 91120 Jerusalem, Israel.

出版信息

Epilepsy Res. 2013 Jan;103(1):2-30. doi: 10.1016/j.eplepsyres.2012.10.001. Epub 2012 Dec 4.

DOI:10.1016/j.eplepsyres.2012.10.001

PMID:23219031

Abstract

The Eleventh Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT XI, took place in Eilat, Israel from the 6th to 10th of May 2012. About 100 basic scientists, clinical pharmacologists and neurologists from 20 countries attended the conference, whose main themes included "Indications overlapping with epilepsy" and "Securing the successful development of an investigational antiepileptic drug in the current environment". Consistent with previous formats of this conference, a large part of the program was devoted to a review of AEDs in development, as well as updates on AEDs introduced since 1994. Like the EILAT X report, the current manuscript focuses only on the preclinical and clinical pharmacology of AEDs that are currently in development. These include brivaracetam, 2-deoxy-glucose, ganaxolone, ICA-105665, imepitoin, NAX 801-2, perampanel and other AMPA receptor antagonists, tonabersat, valnoctamide and its homologue sec-propylbutylacetamide (SPD), VX-765 and YK3089. Since the previous Eilat conference, retigabine (ezogabine) has been marketed and four newer AEDs in development (NAX 810-2, SPD, tonabersat and VX-765) are included in this manuscript.

摘要

第十一届依莱克托新型抗癫痫药物会议（EILAT XI）于 2012 年 5 月 6 日至 10 日在以色列埃拉特举行。约有 100 名来自 20 个国家的基础科学家、临床药理学家和神经学家参加了会议，其主要主题包括“与癫痫重叠的适应症”和“在当前环境下确保研究性抗癫痫药物的成功开发”。与该会议以往的形式一致，大部分计划都用于审查正在开发的 AED 药物，以及自 1994 年以来推出的 AED 药物的更新。与 EILAT X 报告一样，本手稿仅关注目前正在开发的抗癫痫药物的临床前和临床药理学。这些包括布瓦西坦、2-脱氧葡萄糖、加奈索酮、ICA-105665、依美替唑、NAX 801-2、perampanel 和其他 AMPA 受体拮抗剂、tonabersat、valnoctamide 及其同系物 sec-propylbutylacetamide（SPD）、VX-765 和 YK3089。自上次依莱克托会议以来，瑞替加滨（ezogabine）已上市，开发中的四种新型 AED 药物（NAX 810-2、SPD、tonabersat 和 VX-765）包含在本手稿中。